CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors.
Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞治疗实体瘤疗效不佳,原因包括CAR-T 细胞向肿瘤浸润不足、体内扩增和持续存留有限、效应功能不足及细胞耗竭,以及靶癌细胞内在的靶抗原异质性或抗原丢失,此外还有免疫抑制性肿瘤微环境(TME)的影响。本文介绍一种适用范围广的非基因工程策略,可同时应对CAR-T 治疗实体瘤面临的多重挑战。该方法将CAR-T 细胞暴露于经细胞应激诱导剂双硫仑(DSF)和铜(Cu)联合电离辐射(IR)处理的受应激靶癌细胞,使CAR-T 细胞发生大规模重编程。重编程后的CAR-T 细胞获得早期记忆样特征、强效细胞毒性、增强的体内扩增和持续存留能力,且耗竭减少。DSF/Cu和IR处理的应激肿瘤还可在人源化小鼠中重编程并逆转免疫抑制性TME。重编程CAR-T 细胞来源于健康供者或转移性乳腺癌患者的外周血单个核细胞,在多个异种移植小鼠模型中均诱导强劲、持久的记忆反应和具有治愈性的实体瘤应答,初步验证了通过肿瘤应激增强CAR-T 细胞、治疗实体瘤这一新策略。
The poor efficacy of chimeric antigen receptor T-cell therapy (CAR T) for solid tumor is due to insufficient CAR T cell tumor infiltration, in vivo expansion, persistence, and effector function, as well as exhaustion, intrinsic target antigen heterogeneity or antigen loss of target cancer cells, and immunosuppressive tumor microenvironment (TME).
Here we describe a broadly applicable nongenetic approach that simultaneously addresses the multiple challenges of CAR T as a therapy for solid tumors. The approach massively reprograms CAR T cells by exposing them to stressed target cancer cells which have been exposed to the cell stress inducer disulfiram (DSF) and copper (Cu)(DSF/Cu) plus ionizing irradiation (IR). The reprogrammed CAR T cells acquired early memory-like characteristics, potent cytotoxicity, enhanced in vivo expansion, persistence, and decreased exhaustion.
Tumors stressed by DSF/Cu and IR also reprogrammed and reversed immunosuppressive TME in humanized mice. The reprogrammed CAR T cells, derived from peripheral blood mononuclear cells (PBMC) of healthy or metastatic breast cancer patients, induced robust, sustained memory and curative anti-solid tumor responses in multiple xenograft mouse models, establishing proof of concept for empowering CAR T by stressing tumor as a novel therapy for solid tumor.
MEMBER ACCOUNT
登录成功会直接打开下一页。